摘要
AIM: To test protracted irinotecan infusion plus a low-dose cisplatin in this Phase Ⅱ trial to decrease its toxic-ity. METHODS: The eligibility criteria were: (1) histologi-cally proven measurable gastric cancer; (2) performance status of 0 or 1; (3) no prior chemotherapy or comple-tion of prior therapy at least 4 wk before enrollment; (4) adequate function of major organs; (5) no other active malignancy; and (6) written informed consent. The regi-men consisted of irinotecan (60 mg/m2) on d 1 and 15 by 24-h infusion and cisplatin (10 mg/m2) on d 1, 2, 3, 15, 16, and 17. Treatment was repeated every 4 wk. RESULTS: Thirty-one patients were registered between April 2000 and January 2001. The response rate for all 31 patients, 20 patients without prior chemotherapy, and 11 patients with prior chemotherapy was 52% (16/31), 60% (12/20), and 36% (4/11), respectively. The median survival time was 378 d. The median number of courses given to all patients was 2. Grade 4 neutropenia oc-curred in 11 (35%) patients, while grade 3 to 4 diarrhea or nausea occurred in 1 (3%) and 3 (10%) patients, respectively. Fatigue was minimal as grade 1 fatigue was found only in 3 (10%) patients. Other adverse events were mild and no treatment-related deaths occurred.CONCLUSION: This regimen showed a high level of ac-tivity and acceptable toxicity in patients with metastatic gastric cancer.
AIM： To test protracted irinotecan infusion plus a lowdose cisplatin in this Phase Ⅱ trial to decrease its toxicity. METHODS： The eligibility criteria were： （1） histologically proven measurable gastric cancer; （2） performance status of 0 or 1; （3） no prior chemotherapy or completion of prior therapy at least 4 wk before enrollment; （4） adequate function of major organs; （5） no other active malignancy; and （6） written informed consent. The regimen consisted of irinotecan （60 mg/m^2） on d 1 and 15 by 24-h infusion and cisplatin （10 mg/m^2） on d 1, 2, 3, 15, 16, and 17. Treatment was repeated every 4 wk. RESULTS： Thirty-one patients were registered between April 2000 and January 2001. The response rate for all 31 patients, 20 patients without prior chemotherapy, and 11 patients with prior chemotherapy was 52% （16/31）, 60% （12/20）, and 36% （4/11）, respectively. The median survival time was 378 d. The median number of courses given to all patients was 2. Grade 4 neutropenia occurred in 11 （35%） patients, while grade 3 to 4 diarrhea or nausea occurred in 1 （3%） and 3 （10%） patients, respectively. Fatigue was minimal as grade 1 fatigue was found only in 3 （10%） patients. Other adverse events were mild and no treatment-related deaths occurred.
CONCLUSION： This regimen showed a high level of activity and acceptable toxicity in patients with metastatic gastric cancer.
关键词
病理
治疗
临床
胃癌
Gastric cancer
CPT-11
CDDP
Protracted Irinotecan
Chemotherapy
